Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat added to stable sildenafil in symptomatic pulmonary arterial hypertension
2010-018863-40Phase 2Terminated
- Sponsor
- Bayer
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of riociguat in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Bayer. Primary endpoint: Maximum change in supine systolic blood pressure from baseline within 4 hours of dosing. Started Apr 2010; status: terminated.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-018863-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018863-40.